Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ Open
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN
CMAJ Open

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • RSS feeds
Research

Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study

Seth R. Shaffer, Zoann Nugent, Andrew Walkty, B. Nancy Yu, Lisa M. Lix, Laura E. Targownik, Charles N. Bernstein and Harminder Singh
November 16, 2020 8 (4) E737-E746; DOI: https://doi.org/10.9778/cmajo.20190191
Seth R. Shaffer
Internal Medicine (Shaffer, Nugent, Walkty, Bernstein, Singh), University of Manitoba, Winnipeg, Man.; Inflammatory Bowel Disease Centre (Shaffer), University of Chicago Medicine, Chicago, Ill.; CancerCare Manitoba, Research Institute (Nugent, Singh); Community Health Sciences (Yu, Lix, Singh), University of Manitoba, Winnipeg, Man.; Division of Epidemiology and Population Health (Yu), BC Centre for Excellence in HIV/AIDS, Vancouver, BC; Division of Gastroenterology (Targownik), Mount Sinai Hospital, University of Toronto, Toronto, Ont.
MD MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zoann Nugent
Internal Medicine (Shaffer, Nugent, Walkty, Bernstein, Singh), University of Manitoba, Winnipeg, Man.; Inflammatory Bowel Disease Centre (Shaffer), University of Chicago Medicine, Chicago, Ill.; CancerCare Manitoba, Research Institute (Nugent, Singh); Community Health Sciences (Yu, Lix, Singh), University of Manitoba, Winnipeg, Man.; Division of Epidemiology and Population Health (Yu), BC Centre for Excellence in HIV/AIDS, Vancouver, BC; Division of Gastroenterology (Targownik), Mount Sinai Hospital, University of Toronto, Toronto, Ont.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Walkty
Internal Medicine (Shaffer, Nugent, Walkty, Bernstein, Singh), University of Manitoba, Winnipeg, Man.; Inflammatory Bowel Disease Centre (Shaffer), University of Chicago Medicine, Chicago, Ill.; CancerCare Manitoba, Research Institute (Nugent, Singh); Community Health Sciences (Yu, Lix, Singh), University of Manitoba, Winnipeg, Man.; Division of Epidemiology and Population Health (Yu), BC Centre for Excellence in HIV/AIDS, Vancouver, BC; Division of Gastroenterology (Targownik), Mount Sinai Hospital, University of Toronto, Toronto, Ont.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Nancy Yu
Internal Medicine (Shaffer, Nugent, Walkty, Bernstein, Singh), University of Manitoba, Winnipeg, Man.; Inflammatory Bowel Disease Centre (Shaffer), University of Chicago Medicine, Chicago, Ill.; CancerCare Manitoba, Research Institute (Nugent, Singh); Community Health Sciences (Yu, Lix, Singh), University of Manitoba, Winnipeg, Man.; Division of Epidemiology and Population Health (Yu), BC Centre for Excellence in HIV/AIDS, Vancouver, BC; Division of Gastroenterology (Targownik), Mount Sinai Hospital, University of Toronto, Toronto, Ont.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa M. Lix
Internal Medicine (Shaffer, Nugent, Walkty, Bernstein, Singh), University of Manitoba, Winnipeg, Man.; Inflammatory Bowel Disease Centre (Shaffer), University of Chicago Medicine, Chicago, Ill.; CancerCare Manitoba, Research Institute (Nugent, Singh); Community Health Sciences (Yu, Lix, Singh), University of Manitoba, Winnipeg, Man.; Division of Epidemiology and Population Health (Yu), BC Centre for Excellence in HIV/AIDS, Vancouver, BC; Division of Gastroenterology (Targownik), Mount Sinai Hospital, University of Toronto, Toronto, Ont.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura E. Targownik
Internal Medicine (Shaffer, Nugent, Walkty, Bernstein, Singh), University of Manitoba, Winnipeg, Man.; Inflammatory Bowel Disease Centre (Shaffer), University of Chicago Medicine, Chicago, Ill.; CancerCare Manitoba, Research Institute (Nugent, Singh); Community Health Sciences (Yu, Lix, Singh), University of Manitoba, Winnipeg, Man.; Division of Epidemiology and Population Health (Yu), BC Centre for Excellence in HIV/AIDS, Vancouver, BC; Division of Gastroenterology (Targownik), Mount Sinai Hospital, University of Toronto, Toronto, Ont.
MD MSHS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles N. Bernstein
Internal Medicine (Shaffer, Nugent, Walkty, Bernstein, Singh), University of Manitoba, Winnipeg, Man.; Inflammatory Bowel Disease Centre (Shaffer), University of Chicago Medicine, Chicago, Ill.; CancerCare Manitoba, Research Institute (Nugent, Singh); Community Health Sciences (Yu, Lix, Singh), University of Manitoba, Winnipeg, Man.; Division of Epidemiology and Population Health (Yu), BC Centre for Excellence in HIV/AIDS, Vancouver, BC; Division of Gastroenterology (Targownik), Mount Sinai Hospital, University of Toronto, Toronto, Ont.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harminder Singh
Internal Medicine (Shaffer, Nugent, Walkty, Bernstein, Singh), University of Manitoba, Winnipeg, Man.; Inflammatory Bowel Disease Centre (Shaffer), University of Chicago Medicine, Chicago, Ill.; CancerCare Manitoba, Research Institute (Nugent, Singh); Community Health Sciences (Yu, Lix, Singh), University of Manitoba, Winnipeg, Man.; Division of Epidemiology and Population Health (Yu), BC Centre for Excellence in HIV/AIDS, Vancouver, BC; Division of Gastroenterology (Targownik), Mount Sinai Hospital, University of Toronto, Toronto, Ont.
MD MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1:

    Age-standardized CDI rates in Manitoba, 2005 to 2015. Note: CDI = Clostridioides difficile infection, HCF = health care facility.

  • Figure 2:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2:

    Proportion of CDI cases that were community-associated, 2005 to 2015. Note: CDI = Clostridioides difficile infection.

  • Figure 3:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3:

    Inpatient status for all incident and recurrent CDI in the 30 days following laboratory confirmation of CDI among those who were outpatients at CDI onset. Note: CDI = Clostridioides difficile infection.

Tables

  • Figures
    • View popup
    • Download powerpoint
    Table 1:

    Demographic and clinical characteristics of patients with incident or recurrent CDIs

    CharacteristicNo. (%) of patients*
    All patients
    n = 8471
    Incident CDI
    n = 6855
    Recurrent CDI
    n = 1616
    p value†
    Sex, male3549 (41.8)2905 (42.3)644(39.8)0.064
    Age, median (IQR), yr71 (55–82)70 (53–82)77 (63–85)< 0.001
    SEFI, median (IQR)−0.08 (−0.57 to 0.40)−0.07 (−0.57 to 0.40)−0.10 (−0.59 to 0.39)0.30
    No. of ambulatory care visits in the year preceding the index CDI, median (IQR)24 (14–39)22 (13–37)30 (20–45)< 0.001
    Charlson Comorbidity Index
     02339 (27.6)2033 (29.6)306 (18.9)< 0.001
     11491 (17.6)1199 (17.4)292 (18.0)
     21510 (17.8)1195 (17.4)315 (19.4)
     ≥ 33131 (36.9)2428 (35.4)703 (43.5)
    Diabetes2434 (28.7)1956 (28.5)478 (29.5)0.41
    Renal disease1522 (17.9)1208 (17.6)314 (19.4)0.091
    Inflammatory bowel disease280 (3.3)224 (3.2)56 (3.4)0.70
    Type of index CDI (by location of acquisition)
     HCF-onset HCF-associated3563 (42.0)2824 (41.1)739 (45.7)< 0.001
     Community-onset HCF-associated1469 (17.3)1133 (16.5)336 (20.7)
     Community-associated2558 (30.1)2259 (32.9)299 (18.5)
     Indeterminate881 (10.4)639 (9.3)242 (14.9)
    • Note: CDI = Clostridioides difficile infection, HCF = health care facility, IQR = interquartile range, SEFI = Socioeconomic Factor Index.

    • ↵* Except where indicated otherwise.

    • ↵† The comparison is between characteristics of those with incident versus recurrent CDI.

    • View popup
    • Download powerpoint
    Table 2:

    Predictors of recurrent CDI among patients with diagnosis of CDI

    CovariateRecurrence type; adjusted HR (95% CI)*
    First recurrence†Second recurrence‡
    Age, yr (Ref: 18–69 yr)
     70–791.51 (1.27 to 1.79)1.61 (1.14 to 2.28)
     ≥ 802.01 (1.72 to 2.34)2.76 (2.06 to 3.70)
    Female sex (v. male)1.16 (1.02 to 1.32)0.99 (0.78 to 1.25)
    SEFI (Ref: richer v. poorer)0.92 (0.82 to 1.04)0.98 (0.78 to 1.23)
    CCI (Ref: 0)§
     11.23 (1.02 to 1.47)0.83 (0.57 to 1.20)
     21.17 (0.96 to 1.42)1.35 (0.96 to 1.91)
     ≥ 31.18 (0.97 to 1.45)1.23 (0.84 to 1.78)
    Diabetes (v. none)1.06 (0.91 to 1.23)1.00 (0.76 to 1.31)
    Renal disease (v. none)1.07 (0.89 to 1.30)1.17 (0.84 to 1.63)
    IBD (v. none)1.13 (0.79 to 1.63)0.81 (0.36 to 1.83)
    Ambulatory care visits in prior year (v. most)
     Least1.17 (0.96 to 1.43)1.93 (1.20 to 3.11)
     Quartile 21.20 (0.97 to 1.48)1.92 (1.21 to 3.05)
     Quartile 31.10 (0.88 to 1.38)2.12 (1.37 to 3.27)
    CDI subtype (v. community-associated)
     HCF-onset HCF-associated¶1.20 (1.02 to 1.42)1.28 (0.91 to 1.79)
     Community-onset HCF-associated1.25 (1.03 to 1.53)1.51 (1.03 to 2.21)
     Indeterminate1.18 (0.93 to 1.50)1.34 (0.86 to 2.11)
    • Note: CDI = Clostridioides difficile infection, CCI = Charlson Comorbidity Index, CI = confidence interval, HCF = health care facility, HR = hazard ratio, IBD = inflammatory bowel disease, Ref = Reference, SEFI = Socioeconomic Factor Index.

    • ↵* HRs were adjusted for all factors listed in table.

    • ↵† For the first recurrence analysis, we included 5795 incident CDIs with > 14 days follow-up. There were 1021 recurrences (events) and 421 deaths (competing events).

    • ↵‡ For the second recurrence analysis, we included 5558 incident CDIs with > 28 day follow-up. There were 295 recurrences (events) and 500 deaths (competing events).

    • ↵§ Renal disease and diabetes omitted from CCI calculation.

    • ↵¶ In the subgroup analysis of those with HCF-onset HCF-associated CDI (n = 2338), longer hospitalization (> 14 days) before CDI onset was associated with increased risk of both first CDI recurrence (n = 477; HR 1.70 [95% CI 1.40 to 2.06]) as well as the second CDI recurrence (n = 142; HR 1.76 [95% CI 1.23 to 2.52]).

    • View popup
    • Download powerpoint
    Table 3:

    Predictors of severe outcomes among patients with CDI diagnosis*

    CovariateAdjusted OR (95% CI)†
    Age, yr (Ref: 18–69 yr)
     70–791.52 (1.22 to 1.89)
     ≥ 802.44 (2.02 to 2.94)
    Female sex (v. male)0.92 (0.79 to 1.08)
    SEFI‡1.11 (1.02 to 1.20)
    CCI (Ref: 0)§
     11.88 (1.46 to 2.43)
     22.06 (1.59 to 2.66)
     ≥ 32.55 (1.97 to 3.30)
    Diabetes (v. none)0.98 (0.81 to 1.18)
    Renal disease (v. none)1.65 (1.34 to 2.02)
    IBD (v. none)0.82 (0.45 to 1.49)
    Ambulatory care visits in prior year (v. most)
     Least0.69 (0.52 to 0.92)
     Quartile 20.80 (0.64 to 1.01)
     Quartile 30.93 (0.76 to 1.13)
    CDI subtype (v. community-associated)
     HCF-onset HCF-associated¶2.56 (2.02 to 3.25)
     Community-onset HCF-associated1.32 (0.99 to 1.77)
     Indeterminate1.02 (0.71 to 1.49)
    Recurrent CDI (v. incident CDI)0.64 (0.52 to 0.79)
    • Note: CDI = Clostridioides difficile infection, CCI = Charlson Comorbidity Index, CI = confidence interval, HCF = health care facility, IBD = inflammatory bowel disease, OR = odds ratio, SEFI = Socioeconomic Factor Index.

    • ↵* 831 severe outcomes among 6154 patients diagnosed with CDI.

    • ↵† The ORs were adjusted for all the factors listed in the table.

    • ↵‡ SEFI was handled as a continuous variable.

    • ↵§ Renal disease and diabetes omitted from CCI calculation.

    • ↵¶ In the subgroup analysis of those with HCF-onset HCF-associated CDI, longer stay in hospital (> 17 days) before CDI onset was associated with increased risk of severe outcomes (OR 1.36, 95% CI 1.11 to 1.68); 563 severe outcomes among 2568 individuals.

    • View popup
    • Download powerpoint
    Table 4:

    Predictors of admission to hospital within 6 months for outpatients with CDI*

    CovariateAdjusted HR (95% CI)†
    Recurrence (Ref: No recurrence)1.58 (1.31 to 1.91)
    Age, yr (Ref: 18–69 yr)
     70–791.55 (1.25 to 1.92)
     ≥ 801.49 (1.23 to 1.81)
    Male sex (v. female)0.95 (0.81 to 1.11)
    SEFI‡1.17 (1.07 to 1.27)
    CCI (Ref: 0)§
     11.54 (1.2 to 1.96)
     21.35 (1.03 to 1.76)
     ≥ 31.83 (1.43 to 2.36)
    CDI subtype (v. community-associated)
     Community-onset HCF-associated1.46 (1.21 to 1.77)
     Indeterminate1.31 (1.05 to 1.63)
    Ambulatory care visits in previous year (v. least)
     Quartile 21.34 (0.99 to 1.82)
     Quartile 31.84 (1.36 to 2.48)
     Most2.20 (1.6 to 3.02)
    • Note: CDI = Clostridioides difficile infection, CCI = Charlson Comorbidity Index, CI = confidence interval, HCF = health care facility, HR = hazard ratio, SEFI = Socioeconomic Factor Index.

    • ↵* 307 admissions among 2530 outpatients diagnosed with CDI.

    • ↵† The HRs were adjusted for all the factors listed in the table.

    • ↵‡ SEFI was handled as a continuous variable.

    • ↵§ Renal disease and diabetes omitted from CCI calculation.

PreviousNext
Back to top

In this issue

CMAJ Open: 8 (4)
Vol. 8, Issue 4
1 Oct 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ Open.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study
(Your Name) has sent you a message from CMAJ Open
(Your Name) thought you would like to see the CMAJ Open web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study
Seth R. Shaffer, Zoann Nugent, Andrew Walkty, B. Nancy Yu, Lisa M. Lix, Laura E. Targownik, Charles N. Bernstein, Harminder Singh
Oct 2020, 8 (4) E737-E746; DOI: 10.9778/cmajo.20190191

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study
Seth R. Shaffer, Zoann Nugent, Andrew Walkty, B. Nancy Yu, Lisa M. Lix, Laura E. Targownik, Charles N. Bernstein, Harminder Singh
Oct 2020, 8 (4) E737-E746; DOI: 10.9778/cmajo.20190191
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Collections

  • Clinical
    • Gastroenterology
      • Clostridium difficile
      • Drugs: gastrointestinal system
    • Community Medicine
    • Family Medicine, General Practice, Primary Care
      • Other family medicine

Content

  • Current issue
  • Past issues
  • Collections

About

  • General Information
  • Staff
  • Editorial Board
  • Advisory Panel
  • Contact Us
  • Reprints
  • Copyright and Permissions
CMAJ Group

Copyright 2025, CMA Impact Inc. or its licensors. All rights reserved. ISSN 2291-0026

All editorial matter in CMAJ OPEN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].

CMA Civility, Accessibility, Privacy

 

 

Powered by HighWire